Previous 10 | Next 10 |
Pulmonx (LUNG): Q1 GAAP EPS of -$0.34 beats by $0.05.Revenue of $9.2M beats by $1.06M.Press Release For further details see: Pulmonx EPS beats by $0.05, beats on revenue
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the first quarter ended March 31, 2021. ...
REDWOOD CITY, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for lung disease, today announced the company will be participating in a fireside chat at the BofA Securities 2021 Virtual H...
REDWOOD CITY, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2021 after the close of t...
Citi analyst Joanne Wuensch has initiated shares of Pulmonx Corp. (LUNG) with a buy rating and a $60 price target.Given yesterday's closing price, that implies upside of ~31%.She says the company has revolutionized the treatment of emphysema through its Zephyr Valve System.The device has been...
Gilead Sciences (GILD) is trading ~1.6% higher in the pre-market after Bernstein upgraded the stock to outperform from market perform.The analyst Aaron Gal expects that company to generate future catalysts and growth drivers the lack of which led the stock to remain undervalued in the pa...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The energy and shipping markets take center stage next week as the drama in the Suez Canal continues to play out and OPE...
Pulmonx Corporation ([[LUNG]] +10.9%) has risen by more than a tenth today after the analysts at Bank of America raised the stock to buy from neutral noting that recent ~26% selloff has given an attractive entry point given the expected post-COVID surge in demand.The price target is unchanged...
Image source: The Motley Fool. Pulmonx Corporation (NASDAQ: LUNG) Q4 2020 Earnings Call Mar 02, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Pulmonx Corporation (LUNG) Q4 2020 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q4 2020 Earnings Conference Call March 2, 2021 16:30 ET Company Participants Brian Johnston - Investor Relations Glendon French - President & Chief Executive Officer Derrick Sung - Chief Financial Officer Conference Call Participants Robert Hopkins - Bank of Ame...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...